Table 2.
Agent | Principal Targeted Jak(s) | Indication | Development Stage |
---|---|---|---|
Ruxolitinib | Jak1, Jak2 | Myelofibrosis | FDA approved |
Primary polycythemia | Phase III trial | ||
Primary thrombocythemia | Phase II trial | ||
Tofacitinib | Jak3, Jak1 | Rheumatoid arthritis | FDA approval recommended |
Psoriasis, IBD | Phase II trial | ||
Baricitinib | Jak1, Jak2 | Rheumatoid arthritis, Psoriasis | Phase II trial |
CYT387 | Jak2 | Myelofibrosis | Phase II trial |
GLPG-0634 | Jak1 | Rheumatoid arthritis | Phase II trial |
INCB18424 | Jak1, Jak2 | Psoriasis | Phase II trial |
Lestaurtinib | Jak2 | Myelofibrosis | Phase II trial |
Pacritinib | Jak2 | Myelofibrosis | Phase II trial |
VX-509 | Jak3 | Rheumatoid arthritis | Phase II trial |
R-348 | Jak3 | Rheumatoid arthritis | Phase I trial |